[go: up one dir, main page]

AU2001225499A1 - Remedies for hepatitis containing alanine and glycine - Google Patents

Remedies for hepatitis containing alanine and glycine

Info

Publication number
AU2001225499A1
AU2001225499A1 AU2001225499A AU2549901A AU2001225499A1 AU 2001225499 A1 AU2001225499 A1 AU 2001225499A1 AU 2001225499 A AU2001225499 A AU 2001225499A AU 2549901 A AU2549901 A AU 2549901A AU 2001225499 A1 AU2001225499 A1 AU 2001225499A1
Authority
AU
Australia
Prior art keywords
glycine
remedies
alanine
hepatitis
containing alanine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001225499A
Inventor
Ichiro Sonaka
Masayoshi Yamauchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Publication of AU2001225499A1 publication Critical patent/AU2001225499A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Hepatitis remedy comprises alanine and glycine. ACTIVITY : Antiinflammatory; Hepatotropic. In assays using HepG2 cells addition of glycine and alanine at 0.02 mM significantly reduced galactosamine induced cell death (p is less than 0.05) compared to control or addition of glycine (0.1 mM). MECHANISM OF ACTION : None Given.
AU2001225499A 2000-01-18 2001-01-12 Remedies for hepatitis containing alanine and glycine Abandoned AU2001225499A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2000008658 2000-01-18
JP2000-8658 2000-01-18
JP2000-60097 2000-03-06
JP2000060097 2000-03-06
PCT/JP2001/000109 WO2001052834A1 (en) 2000-01-18 2001-01-12 Remedies for hepatitis containing alanine and glycine

Publications (1)

Publication Number Publication Date
AU2001225499A1 true AU2001225499A1 (en) 2001-07-31

Family

ID=26583682

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001225499A Abandoned AU2001225499A1 (en) 2000-01-18 2001-01-12 Remedies for hepatitis containing alanine and glycine

Country Status (7)

Country Link
US (1) US7208523B2 (en)
EP (1) EP1249235B1 (en)
AT (1) ATE334667T1 (en)
AU (1) AU2001225499A1 (en)
DE (1) DE60121913T2 (en)
ES (1) ES2264437T3 (en)
WO (1) WO2001052834A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1656933A1 (en) * 2004-11-11 2006-05-17 Ajinomoto Co., Inc. A medicinal composition comprising L-alanine for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis and use therof
JPWO2006061992A1 (en) * 2004-12-10 2008-06-05 味の素株式会社 Liver disease prevention / treatment composition
WO2007142297A1 (en) * 2006-06-09 2007-12-13 Ajinomoto Co., Inc. Composition for prevention/treatment of hepatic disease
GB201019628D0 (en) * 2010-11-19 2010-12-29 Reckitt Benckiser Nv Dyed coated bleach materials

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51115909A (en) * 1975-04-01 1976-10-13 Otsuka Pharmaceut Factory Inc A process for preparing amino acid parenteral injection mixed with a r educing sugar
DE2636828A1 (en) * 1976-08-16 1978-02-23 Fresenius Chem Pharm Ind (L)-Aminoacid mixt. for treating liver insufficiency - contains isoleucine, leucine, lysine, methionine and cysteine or cystine and non-essential aminoacid(s)
JPS58126767A (en) * 1982-01-22 1983-07-28 Ajinomoto Co Inc Elemental diet for hepatopathic patient
US4491589A (en) * 1982-05-17 1985-01-01 The Trustees Of Columbia University In The City Of New York Amino acid solutions for parenteral nutrition and methods of formulation and use
SU1470739A1 (en) * 1984-07-16 1989-04-07 Всесоюзный кардиологический научный центр АМН СССР Hexapeptide displaying hepatoprotective traits
JP3127484B2 (en) * 1991-02-28 2001-01-22 味の素株式会社 Hepatitis treatment
CA2078712A1 (en) * 1991-09-23 1993-03-24 Bernhard Sixt Composition comprising amino acids for the prevention of hypoxic damage and a process for its preparation
JP3168669B2 (en) * 1992-02-26 2001-05-21 味の素株式会社 Liver regeneration promoter
GB9512100D0 (en) * 1995-06-14 1995-08-09 Sandoz Nutrition Ltd Improvements in or relating to organic compounds

Also Published As

Publication number Publication date
US7208523B2 (en) 2007-04-24
ATE334667T1 (en) 2006-08-15
WO2001052834A1 (en) 2001-07-26
EP1249235B1 (en) 2006-08-02
EP1249235A1 (en) 2002-10-16
DE60121913D1 (en) 2006-09-14
DE60121913T2 (en) 2007-03-01
ES2264437T3 (en) 2007-01-01
EP1249235A4 (en) 2004-07-28
US20020198262A1 (en) 2002-12-26

Similar Documents

Publication Publication Date Title
Silverman et al. Reduced thioredoxin: a possible physiological cofactor for vitamin K epoxide reductase. Further support for an active site disulfide
MX9708678A (en) Soluble, active hepatitis c virus protease.
IL204319A (en) Kit for incorporation of single oxygen atom into a digested peptide of a protein comprising a peptidase and enriched 18o water
ID26669A (en) INTI HEPATITIS B PROTEINS MODIFIED BY STRATEGY AND ITS DECREASES
WO2002088346A3 (en) A system for inducible expression in eukaryotic cells
DK1043399T3 (en) Hepatitis C Virus cell culture system
IL128826A0 (en) A crystallizable composition comprising a hepatitis C virus NS3 like polypeptide complexed with a NS4 a-like peptide
DE69932424D1 (en) MELANOCORTIN 1 RECEPTOR-SELECTIVE COMPOUNDS
AU1279900A (en) Nightwear for children or incontinent persons
EP1211512A3 (en) Test strip for determining dialysate composition
AU2001225499A1 (en) Remedies for hepatitis containing alanine and glycine
Burzynski et al. Biological active peptides in human urine: III. Inhibitors of the growth of human leukemia, osteosarcoma, and HeLa cells
Han et al. Mechanistic studies of the biosynthesis of 3, 6-dideoxyhexoses in Yersinia pseudotuberculosis. Purification and characterization of CDP-6-deoxy-delta 3, 4-glucoseen reductase based on its NADH: dichlorophenolindolphenol oxidoreductase activity.
WO2000006750A3 (en) Method for autoactivation of procaspase 8
CY1112542T1 (en) USE OF A ESTROGEN FOR THE INDUSTRIAL CONSTRUCTION OF A COMPOSITION CONTAINING ESTROGEN FOR THE TREATMENT OF Atrophic Colitis
IE810114L (en) N-benzyloxycarbonyl-l-aspartic acid
Lasson et al. On the potential role of trypsin and trypsin inhibitors in acute pancreatitis
Gehring et al. Amino acid sequence around the reactive cysteine residues in thiolase
TR200101901T2 (en) 5 - [{6- (2-Fluorobenzyl) oxy-2-naphthyl} methyl] -2,4-Thiazolidine dion crystals
AU5069800A (en) Novel gbv sequence
Inano Chemical modification of lysine residues at active-site of human placental estradiol 17β-dehydrogenase
AU4269401A (en) HCV NS2/3 fragments and uses thereof
Gutteridge et al. Iron Binding and Autoreduction by Citrate: Are These Involved in Signalling by Iron Regulatory Protein-l?
AU1751501A (en) Composition of matter tailoring: system i
KATAYAMA et al. A simple purification procedure for rat pancreatic elastase and radioimmunoassay of the enzyme